Wellness & Lifestyle

xLM - Continuous Intelligence provides AI-driven solutions specifically designed to streamline GxP compliance within the life sciences sector. The platform offers a suite of services including Continuous Intelligent Validation (cIV) for automating software validation, Continuous Temperature Mapping (cTM) for environmental monitoring, and Continuous Predictive Maintenance (cPdM) to prevent equipment failures. These tools leverage advanced AI, machine learning, and predictive analytics to automate tasks like URS creation, test case generation, and GxP-compliant reporting. By focusing on continuous validation and monitoring, xLM helps organizations reduce risk, accelerate operations, and ensure adherence to regulatory standards across manufacturing and operational processes.

Deep Forest Sciences has developed Prithvi, an AI assistant designed to accelerate scientific discoveries in medicine and materials. Powered by the DeepChem infrastructure, Prithvi utilizes large scientific foundation models and cutting-edge AI techniques on proprietary data to provide AI-driven insights. It has been successfully deployed on various projects including drug discovery, energy, and molecular design. The platform also supports no-code fine-tuning of chemical foundation models, relative binding free energy calculations, molecular dynamics, and DEL-ML analysis, making advanced scientific AI accessible to researchers.

Premium Research is a company specializing in key areas such as artificial intelligence, including machine learning, computer vision, and digital twins. They also focus on bioinformatics, biostatistics, omics and metabolomics studies, genetics, and nanotechnology. The company develops European and national R&D+i projects funded by public grants, such as Horizon Europe and national PERTE and CDTI programs. Additionally, Premium Research offers services in the production of scientific articles, brochures, and specialized posters. In open innovation, they excel in technology watch, community building, and collaboration networks, with a special focus on innovative startups.

Verge Genomics has pioneered an advanced all-in-human AI-powered drug discovery platform, focusing on developing new drugs for major medical challenges. The platform leverages human genomics, machine learning, biological engineering, and translational medicine to decipher disease biology. Instead of relying on animal or cell models, Verge Genomics utilizes one of the world's largest proprietary multi-omics databases derived directly from human tissue. This approach allows them to map complex disease causes and develop proprietary drug candidates. Their first drug, VRG50635, for amyotrophic lateral sclerosis (ALS), moved from research to clinic in just four years, demonstrating the platform's efficiency. They are also working on treatments for Parkinson's Disease and Frontotemporal Dementia.

KOL Pulse AI is an AI-powered platform designed for oncology intelligence, offering real-time insights into Key Opinion Leaders (KOLs) and clinical trials. It provides verified social intelligence from major oncology conferences, clinical trials, and OpenPayments data, ensuring all insights are sourced, cited, and audited. The platform features AI-generated trial intelligence with real slides and KOL commentary, including sentiment analysis and engagement leaderboards. Users can track KOL sentiment, influencer networks, and social engagement maps. KOL Pulse AI also offers 26 embeddable widgets for integrating live KOL intelligence into any website or AI platform, making it accessible for medical affairs, insights, and med comms teams.

Aiku specializes in enabling individuals and teams to innovate and build with AI, moving beyond theoretical concepts to practical implementation. Their services encompass data engineering, machine learning, and data automation, designed to guide clients through every stage of their AI journey. Aiku helps lay the foundation for data analytics by organizing data pipelines and providing ready-to-use data. They also assist in leveraging artificial intelligence and predictive models to gain critical insights for better decision-making. Furthermore, Aiku supports the publication of data products through interactive web applications and provides ongoing service and support for software deployment and maintenance. They offer specialized solutions for marketing, sales, production, and research & development, including custom machine learning and data mining services.

HITS is an AI-driven biotech company focused on revolutionizing drug discovery through advanced artificial intelligence. Their platform, Hyper Lab, offers a suite of products including Hyper ADME/T for predicting drug properties, Hyper Design for novel molecule design, Hyper Binding for drug-protein interaction analysis, and Hyper Screening for efficient hit identification. HITS integrates physics-based modeling with deep learning to rapidly identify effective compounds and design new drug structures. The company aims to make AI-powered drug development accessible and efficient, reducing costs and accelerating the timeline from discovery to market.

Basetwo AI is an AI platform designed for process engineers to optimize manufacturing operations. It leverages AI-powered digital twins to shift from physical to virtual experiments, reducing experimentation time by 40-50% and accelerating time to market. The platform helps reduce manufacturing costs and cycle time by 20-40% through AI-powered setpoints. It also ensures consistent product quality and an 80% reduction in deviations using real-time soft sensors that predict and correct issues. Basetwo AI offers an all-in-one solution to connect plant and lab databases, build explainable digital twins, and receive actionable recommendations for industries like pharmaceuticals, specialty chemicals, and consumer packaged goods.

Vibe Bio offers an AI-powered platform, VibeOne, designed to help biopharmaceutical companies make smarter drug decisions. The platform leverages AI to sift, organize, and structure vast amounts of data, deriving critical insights for drug discovery and development. It aims to accelerate asset diligence by up to 8x, reduce SME workloads by 75%, and identify 50% more potential assets. Vibe Bio also invests in founders committed to finding cures for rare and overlooked diseases, combining AI analytics with venture funding to drive impact in the biopharma sector.

Partex.AI is the world's largest AI-powered therapeutic asset accelerator, dedicated to solving inefficiencies in drug discovery and development. By utilizing Big Data and Generative AI, Partex.AI optimizes therapeutic assets from the lab to the patient, aiming for clinical success. The platform identifies late-stage preclinical and early clinical drug assets with strong scientific foundations but suboptimal development paths, using proprietary models to optimize them. Partex.AI also facilitates AI-driven in- and out-licensing for pharma and biotech partners, enabling efficient pipeline optimization. Furthermore, it drives the future of AI-powered drug discovery through its Labs, specializing in next-generation functional assays and high-throughput experimental screening. The company also builds global partnerships to leverage Real-World Data for drug development and treatment optimization.

Entvin is an AI-powered regulatory agent specifically designed to assist in the complex process of drug development. The platform leverages artificial intelligence to enhance decision-making and ensure compliance throughout various stages. Key offerings include Labeling AI, which helps in the accurate and compliant generation of drug labels, and Ads Promo AI, which assists in creating promotional materials that adhere to regulatory guidelines. By providing intelligent assistance, Entvin aims to significantly accelerate drug development processes, reducing time-to-market and minimizing regulatory risks. This tool is particularly valuable for pharmaceutical companies and regulatory affairs professionals seeking to streamline their operations and maintain high standards of compliance.

Pharmesol is an AI-powered pharmacy assistant designed to automate various tasks within pharmacy operations, including calls, SMS, document processing, and workflows. It integrates with existing Pharmacy Management Systems (PMS) like PioneerRx, FrameworkLTC, and WellSky to streamline operations. The tool handles hundreds of tasks per hour, such as refill requests, intake calls, prescription status checks, payment collection, prior authorizations, and delivery coordination. Pharmesol aims to free up pharmacy staff to focus on patient care by resolving a majority of calls without human intervention, reducing phone volume, and automating documentation and data processing. It is HIPAA compliant and SOC 2 Type II certified, ensuring patient data privacy and security.

Remedium AI leverages the power of artificial intelligence to revolutionize drug discovery by addressing critical inefficiencies in the pharmaceutical industry. The company has developed a sophisticated structural bioinformatics software platform that utilizes machine learning techniques to analyze proteins with known or suspected therapeutic value. This platform offers significantly greater accuracy than comparable AI tools and provides solutions that are orders of magnitude faster than conventional strategies. By rapidly identifying potential drug candidates, Remedium AI aims to reduce development costs and accelerate the drug discovery process, ultimately igniting a paradigm shift in pharmaceutical drug development through radical formulations for protein-based drugs.

Mass General Brigham AI is an initiative within the integrated healthcare system that leverages artificial intelligence and machine learning to address complex medical problems and enhance patient care. It focuses on developing and integrating clinically relevant AI solutions across various medical disciplines, including research into Alzheimer's Disease and brain imaging for neurological conditions like Parkinson's. The program supports the entire AI product lifecycle, from initial concept and development through to deployment and integration within clinical settings, aiming to improve diagnostics, treatment strategies, and overall healthcare delivery.

JeriMed.ai is an AI-powered platform designed for medication optimization, specifically targeting geriatric care providers. It offers evidence-based insights to confidently reduce medications and associated costs, while safely improving resident health. Key features include timely risk insights based on patient data, polypharmacy hub analysis, and evidence-based medication optimization suggestions. The platform helps prevent adverse drug events, identifies high-risk drug combinations, and supports cost savings through comprehensive medication reviews. JeriMed.ai transforms clinical data into actionable guidance, providing temporal insights to track progress at both patient and population levels, and personalizes medication decisions with real-world clinical context.

Atlas-Compliance is an AI-powered platform designed for life science companies to manage and analyze FDA compliance data. It offers inspector intelligence, allowing users to track inspector history, citation trends, and enforcement behavior for proactive preparation. The tool provides real-time compliance alerts on Form 483s, warning letters, and inspection outcomes. Its AI Copilot enables instant searching, summarizing, and extraction of key insights from thousands of FDA documents. Atlas-Compliance centralizes regulatory data, including inspection reports and warning letters, into one searchable platform, empowering teams to move from reactive to proactive compliance management and make data-driven decisions faster.

Strongbytes is an engineering partner focused on building AI-first products, offering expertise in advanced AI systems, modern data foundations, and end-to-end product delivery. They work with organizations across healthcare, fintech, people analytics, education, automotive, and the public sector to adopt AI safely and at scale. Their services include developing AI products and agentic systems like copilots and intelligent automation, as well as providing AI evaluation and observability to measure behavior, monitor performance, and continuously improve AI systems. Strongbytes also offers comprehensive product engineering for SaaS applications and APIs, alongside data and ML foundations for reliable data pipelines, governance, and scalable analytics. They are the creators of Aegis, an AI evaluation platform specifically for GenAI systems.

Lifio.ai is an AI-driven SaaS platform designed to automate processes within clinical trials, transforming raw information into actionable intelligence at an accelerated pace. The platform harnesses the power of artificial intelligence, machine learning, and natural language processing to streamline complex workflows. By focusing on improving the efficiency of clinical research, Lifio.ai aims to reduce manual effort, enhance data analysis, and provide faster insights, ultimately contributing to more effective and timely outcomes in the pharmaceutical and biotech sectors. Its core mission is to make information processing smarter and quicker for research professionals.

PENTAVERE, a Healwell AI company, is a patient identification company that leverages a best-in-class AI engine, DARWEN™, to identify patients eligible for approved medications or interventions. This technology aims to improve patient outcomes and drive therapy growth by extracting insights from clinical information that is impossible for humans to analyze alone. DARWEN™ automates data abstraction from unstructured hospital electronic medical records, eliminating the need for manual chart review. The tool has received acclaim from major global pharmaceutical companies and healthcare leaders for its ability to generate real-world evidence and provide accurate snapshots of current clinical practices, particularly in areas like lung cancer and rare diseases. PENTAVERE's AI facilitates the creation and maintenance of high-quality clinical databases, improving clinical decision-making and evidence-based practice.

Synteny leverages frontier AI, specifically its MANIFOLD™ intelligence, to address the grand challenge of molecular recognition in biology. By unifying sequence, structure, and physics, the platform learns the hidden logic of life, enabling the decoding of biological cognition. This advanced AI approach aims to transform molecular interactions from an intractable problem into programmable biology. Synteny focuses on designing precision TCR bispecific therapies, utilizing high-throughput data and generative AI to achieve this goal. The company's mission is to translate biology to end disease through innovative engineering and programming.

NoHarm.ai is an intelligent system designed to assist clinical pharmacists in decision-making by leveraging Artificial Intelligence. It integrates with hospital data to optimize pharmaceutical validation, prioritize non-standard prescriptions, and identify critical patients, thereby enhancing care quality and hospital efficiency. Key features include alerts for altered exams, risk indicators for patient evolution based on clinical texts, detection of drug interactions, and identification of out-of-standard prescriptions. The system also offers a prioritization screen to filter and order prescriptions, along with various reports for clinical pharmacy indicators, including risk management and antimicrobial stewardship. It aims to improve patient safety and streamline pharmacists' workflows.

Tempus AI is a leading precision medicine platform that utilizes artificial intelligence to analyze vast amounts of clinical and molecular data, creating the world's largest library of such information. This operating system makes complex data accessible and useful, primarily focusing on cancer treatment. The platform empowers healthcare providers, particularly doctors and oncologists, to make more informed treatment decisions by accelerating the discovery of novel targets, predicting treatment effectiveness, identifying life-saving clinical trials, and diagnosing diseases earlier. Tempus also assists pharmaceutical and biotech companies in drug development and helps patients find optimal therapy options. Key offerings include AI-enabled assistants like Tempus ONE, the NEXT platform for care gap identification, Tempus LENS for real-world data analysis, and ALGOS for algorithmic insights connected to assays.

Raycaster is an AI-native workspace specifically designed for the biopharmaceutical industry, aiming to accelerate drug development by streamlining document management. It ensures that protocols, reports, Module 2/3, and quality documents remain consistent and synchronized with the underlying scientific data. The platform offers features like regulatory research across various documents, AI-powered drafting of protocols and reports, and impact analysis to trace changes across the entire dossier. Raycaster helps teams spend less time on document reconciliation and more on scientific interpretation, ultimately leading to stronger submissions with significantly reduced rework for clinical, CMC, regulatory, quality, and nonclinical teams.

Caidera is an AI-powered marketing compliance platform specifically designed for the life sciences industry, including pharma, medtech, and biotech. It automates the review process, reducing compliance approval times from weeks to minutes by bringing marketing, medical, regulatory, and compliance teams into one AI workspace. The platform features a Compliance Engine for AI-powered regulatory review and a Content Studio for creating brand-aligned content. It covers all relevant compliance regulations, including pharmaceutical, medical device, biotech, data protection (GDPR), and EU AI Act compliance. Caidera integrates seamlessly with existing workflows and systems like Veeva Vault, SharePoint, Google Drive, and Salesforce, ensuring data security with EU data residency and enterprise-grade infrastructure on Microsoft Azure. It supports various content types, from digital and long-form to visual assets and patient education materials.